The global biologics and advanced therapies (ATs) market returned to strong growth in 2024, expanding 14% year-over-year to $474 billion. Oncology, immunology, and metabolic disease therapies, particularly GLP-1 analogs, were the primary growth drivers, alongside increasing approvals of cell and gene therapies. This surge intensified the need for specialized contract development and manufacturing organization (CDMO) services, including monoclonal antibody production, viral vector manufacturing, and flexible fill-finish capabilities.

In 2025, biologics CDMOs face both opportunities and operational challenges as sponsors increasingly seek integrated, end-to-end solutions to support the commercialization of complex modalities. This article explores the key drivers of biologics CDMO growth in 2025, including market demand, AT commercialization, and technology-enabled integration. It also covers the main constraints in this market, including geopolitical uncertainty, macroeconomic pressures, and supply chain fragility.

What Drives Biologics CDMOs Growth in 2025

Rising Demand for Biologic Therapies

The increasing prevalence of chronic and complex conditions such as cancer, autoimmune diseases, diabetes, and obesity continues to support strong demand for biologic therapies. Modalities such as monoclonal antibodies, GLP-1 analogs, gene therapies, and vaccines often require specialized formulation, sterile processing, and controlled distribution. Demand is particularly acute for large-scale monoclonal antibody manufacturing and flexible fill-finish formats such as prefilled syringes and autoinjectors. Consequently, outsourcing to CDMOs with established biologics infrastructure and compliance maturity remains a strategic priority for sponsors.

Commercialization of Advanced Modalities

The approval of several ATs in 2024 generated a new wave of commercial-scale supply needs. The approved ATs included such treatments as:

• exa-cel, CRISPR-based therapy for sickle cell disease and β-thalassemia.
• Beqvez^®, Pfizer’s adeno-associated virus (AAV)-based gene therapy for hemophilia B, approved in Europe.
• Aucatzyl^®, Autolus’ CAR-T therapy for leukemia, recently approved in the US.

These therapies require CDMOs with capabilities across viral vector production, cell processing, analytical development, and cold chain logistics. Their launches, while still early, signal a broader shift in CDMO engagement from mostly clinical-stage support to full lifecycle commercialization of advanced therapy medicinal products (ATMPs).

Integration and Digital Transformation in CDMOs

Leading CDMOs are accelerating investments in upstream vertical integration, including proprietary cell line development, media optimization, and standardized process platforms. In parallel, CDMOs are deploying advanced digital tools, including:

• Artificial intelligence-powered quality control systems.
• Manufacturing execution systems.
• Electronic batch records.
• Real-time release testing.

These initiatives improve scalability, cost efficiency, and regulatory transparency. Such factors are increasingly critical for winning high-value clinical and commercial contracts in a modality-diverse market.

Regulatory Clarity for ATMPs

In 2024, regulatory agencies including the Food and Drug Administration and the European Medicines Agency released updated guidance to increase predictability and efficiency in the development and commercialization of cell and gene therapies. These updates had multiple goals, including the creation of:

• Clarified chemistry, manufacturing, and controls expectations.
• Improved comparability frameworks.
• Expanded engagement channels for rare disease programs.

While fast-track and rolling review pathways previously existed, these reforms enhanced sponsor confidence in regulatory pathways and encouraged earlier-stage investment. As a result, demand increased for CDMOs capable of supporting ATMP programs across viral vector manufacturing, closed-system processing, and cold-chain distribution.

What Constrains Biologics CDMO Growth

Geopolitical Uncertainty and Shifting Trade Policies

In 2024, geopolitical tensions, particularly between the US and China, created operational uncertainty for CDMOs with global or China-dependent footprints. Proposed US legislation, such as the Biosecure Act, raised national security concerns regarding service providers. These concerns most notably impacted China-linked CDMOs involved in federally funded R&D or clinical trial support. The legislation was not enacted but the reputational and compliance risks prompted several sponsors to reassess outsourcing strategies and geographic dependencies. This introduced friction in contract execution, supplier qualification, and long-term regional investment planning.

Macroeconomic Pressure and Tightening Capital Markets

Persistent inflation and high interest rates throughout 2024 placed sustained pressure on CDMO cost structures, particularly across energy, labor, and consumables. Small and mid-sized CDMOs were disproportionately affected. Tighter margins and limited pricing power slowed infrastructure expansion and digitalization initiatives. Concurrently, venture capital pullback and constrained institutional funding delayed or downsized projects from early-stage biopharma clients. These trends widened the performance gap between large-cap CDMOs and capital-constrained players, fueling a wave of consolidation activity across the sector.

Supply Chain Bottlenecks in Biologics

Despite partial normalization post-pandemic, biologics supply chains remained fragile in 2024. The following key inputs faced allocation challenges and extended lead times:

• Single-use bioreactor bags
• GMP-grade viral vectors
• Chromatography resins
• Cold-chain components

Disruptions in sterile fill-finish components, such as vials and stoppers, also contributed to execution delays. These pressures increased reliance on safety stock and prolonged qualification of alternate suppliers. They also forced CDMOs to redesign procurement workflows to maintain GMP continuity and delivery assurance.

Conclusion

The biologics CDMO market is set to maintain solid momentum in the second part of 2025, driven by sustained demand for high-value therapies such as GLP-1s, bispecific antibodies, and viral vector platforms.

Commercialization of complex modalities, adoption of vertically integrated and technology-enabled operations, and regulatory clarity that supports ATMP development will fuel growth. On the other hand, the sector continues to face constraints from geopolitical uncertainty, macroeconomic pressures, and persistent supply chain fragility.

Success will favor CDMOs that pair operational agility with advanced compliance and digital quality systems. This is especially true if they can offer the scale and end-to-end capabilities sponsors now demand across multiple modalities. The winners will be CDMOs that not only deliver technical excellence but also act as strategic partners, helping their clients bring the next generation of biologics and ATs to patients faster, safer, and more reliably.

Go Beyond Market Insights

If you are interested in working with our experts in this market, learn more about our biologics CDMO consulting support.